Adicet Bio (NASDAQ:ACET - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.30), FiscalAI reports.
Adicet Bio Price Performance
ACET stock traded down $0.10 on Wednesday, reaching $9.11. The company had a trading volume of 43,216 shares, compared to its average volume of 130,012. The company's fifty day moving average is $8.36 and its 200 day moving average is $7.81. The company has a market cap of $85.18 million, a P/E ratio of -0.61 and a beta of 1.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.65 and a current ratio of 7.66. Adicet Bio has a 1 year low of $6.01 and a 1 year high of $17.44.
Institutional Trading of Adicet Bio
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Luminus Management LLC purchased a new stake in Adicet Bio during the 4th quarter worth about $501,000. ADAR1 Capital Management LLC acquired a new position in Adicet Bio in the 4th quarter valued at about $1,083,000. Burkehill Global Management LP purchased a new position in Adicet Bio in the 4th quarter valued at about $526,000. Adage Capital Partners GP L.L.C. purchased a new position in Adicet Bio in the 4th quarter valued at about $2,310,000. Finally, Squarepoint Ops LLC boosted its stake in shares of Adicet Bio by 20.0% during the 4th quarter. Squarepoint Ops LLC now owns 55,723 shares of the company's stock worth $469,000 after purchasing an additional 9,296 shares during the last quarter. 83.89% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the company. Weiss Ratings upgraded Adicet Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, May 26th. Wall Street Zen upgraded Adicet Bio from a "sell" rating to a "hold" rating in a research report on Saturday, May 16th. Finally, Jefferies Financial Group began coverage on Adicet Bio in a report on Tuesday, May 5th. They issued a "buy" rating and a $19.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $48.80.
Get Our Latest Stock Report on ACET
Adicet Bio Company Profile
(
Get Free Report)
Adicet Bio, Inc NASDAQ: ACET is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company's proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.
Adicet's lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Adicet Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.
While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
